The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration.
The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).
West Nile virus (WNV) is a mosquito-borne virus that can cause severe disease affecting the brain and nervous system, especially in older adults and people with weakened immune systems. There is no approved human vaccine or specific antiviral treatment for WNV.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen.
Inventors at the National Eye Institute are seeking research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method, (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamper-less tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution MR imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, or in other applications.
The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation.
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.
NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.